Literature DB >> 28103321

Derivative of Extremophilic 50S Ribosomal Protein L35Ae as an Alternative Protein Scaffold.

Anna V Lomonosova1, Andrei B Ulitin2, Alexei S Kazakov1, Tajib A Mirzabekov2,3, Eugene A Permyakov1, Sergei E Permyakov1.   

Abstract

Small antibody mimetics, or alternative binding proteins (ABPs), extend and complement antibody functionality with numerous applications in research, diagnostics and therapeutics. Given the superiority of ABPs, the last two decades have witnessed development of dozens of alternative protein scaffolds (APSs) for the design of ABPs. Proteins from extremophiles with their high structural stability are especially favorable for APS design. Here, a 10X mutant of the 50S ribosomal protein L35Ae from hyperthermophilic archaea Pyrococcus horikoshii has been probed as an APS. A phage display library of L35Ae 10X was generated by randomization of its three CDR-like loop regions (repertoire size of 2×108). Two L35Ae 10X variants specific to a model target, the hen egg-white lysozyme (HEL), were isolated from the resulting library using phage display. The affinity of these variants (L4 and L7) to HEL ranges from 0.10 μM to 1.6 μM, according to surface plasmon resonance data. While L4 has 1-2 orders of magnitude lower affinity to HEL homologue, bovine α-lactalbumin (BLA), L7 is equally specific to HEL and BLA. The reference L35Ae 10X is non-specific to both HEL and BLA. L4 and L7 are more resistant to denaturation by guanidine hydrochloride compared to the reference L35Ae 10X (mid-transition concentration is higher by 0.1-0.5 M). Chemical crosslinking experiments reveal an increased propensity of L4 and L7 to multimerization. Overall, the CDR-like loop regions of L35Ae 10X represent a proper interface for generation of functional ABPs. Hence, L35Ae is shown to extend the growing family of protein scaffolds dedicated to the design of novel binding proteins.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28103321      PMCID: PMC5245882          DOI: 10.1371/journal.pone.0170349

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  50 in total

Review 1.  A new generation of protein display scaffolds for molecular recognition.

Authors:  Ralf J Hosse; Achim Rothe; Barbara E Power
Journal:  Protein Sci       Date:  2006-01       Impact factor: 6.725

Review 2.  Single-domain antibodies as building blocks for novel therapeutics.

Authors:  Dirk Saerens; Gholamreza Hassanzadeh Ghassabeh; Serge Muyldermans
Journal:  Curr Opin Pharmacol       Date:  2008-08-22       Impact factor: 5.547

3.  Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay.

Authors:  J D Beatty; B G Beatty; W G Vlahos
Journal:  J Immunol Methods       Date:  1987-06-26       Impact factor: 2.303

Review 4.  Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept.

Authors:  Thierry Wurch; Alain Pierré; Stéphane Depil
Journal:  Trends Biotechnol       Date:  2012-09-01       Impact factor: 19.536

5.  Tolerance of the archaeal Sac7d scaffold protein to alternative library designs: characterization of anti-immunoglobulin G Affitins.

Authors:  Ghislaine Béhar; Marco Bellinzoni; Mike Maillasson; Lauranne Paillard-Laurance; Pedro M Alzari; Xuemei He; Barbara Mouratou; Frédéric Pecorari
Journal:  Protein Eng Des Sel       Date:  2013-01-11       Impact factor: 1.650

Review 6.  Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs.

Authors:  Christian Jost; Andreas Plückthun
Journal:  Curr Opin Struct Biol       Date:  2014-07-15       Impact factor: 6.809

Review 7.  Recombinant antibody technology: its advent and advances.

Authors:  N Hozumi; J S Sandhu
Journal:  Cancer Invest       Date:  1993       Impact factor: 2.176

8.  Jalview Version 2--a multiple sequence alignment editor and analysis workbench.

Authors:  Andrew M Waterhouse; James B Procter; David M A Martin; Michèle Clamp; Geoffrey J Barton
Journal:  Bioinformatics       Date:  2009-01-16       Impact factor: 6.937

9.  Analysis Tool Web Services from the EMBL-EBI.

Authors:  Hamish McWilliam; Weizhong Li; Mahmut Uludag; Silvano Squizzato; Young Mi Park; Nicola Buso; Andrew Peter Cowley; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2013-05-13       Impact factor: 16.971

10.  Potent and specific inhibition of glycosidases by small artificial binding proteins (affitins).

Authors:  Agustín Correa; Sabino Pacheco; Ariel E Mechaly; Gonzalo Obal; Ghislaine Béhar; Barbara Mouratou; Pablo Oppezzo; Pedro M Alzari; Frédéric Pecorari
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.